TR201902023T4 - Smac mimetikleri olarak 6-alkinil-piridin türevleri. - Google Patents

Smac mimetikleri olarak 6-alkinil-piridin türevleri. Download PDF

Info

Publication number
TR201902023T4
TR201902023T4 TR2019/02023T TR201902023T TR201902023T4 TR 201902023 T4 TR201902023 T4 TR 201902023T4 TR 2019/02023 T TR2019/02023 T TR 2019/02023T TR 201902023 T TR201902023 T TR 201902023T TR 201902023 T4 TR201902023 T4 TR 201902023T4
Authority
TR
Turkey
Prior art keywords
methyl
salts
compounds
compound
pyridine
Prior art date
Application number
TR2019/02023T
Other languages
English (en)
Turkish (tr)
Inventor
Reiser Ulrich
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TR201902023T4 publication Critical patent/TR201902023T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2019/02023T 2014-08-11 2015-08-10 Smac mimetikleri olarak 6-alkinil-piridin türevleri. TR201902023T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14180554 2014-08-11

Publications (1)

Publication Number Publication Date
TR201902023T4 true TR201902023T4 (tr) 2019-03-21

Family

ID=51300621

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02023T TR201902023T4 (tr) 2014-08-11 2015-08-10 Smac mimetikleri olarak 6-alkinil-piridin türevleri.

Country Status (34)

Country Link
US (4) US9481673B2 (enExample)
EP (1) EP3180339B1 (enExample)
JP (1) JP6250226B2 (enExample)
KR (1) KR102445744B1 (enExample)
CN (2) CN111440164B (enExample)
AP (1) AP2017009718A0 (enExample)
AR (1) AR101479A1 (enExample)
AU (1) AU2015303308B2 (enExample)
BR (1) BR112017002498B1 (enExample)
CA (1) CA2956123C (enExample)
CL (1) CL2017000326A1 (enExample)
CO (1) CO2017001226A2 (enExample)
CY (1) CY1121273T1 (enExample)
DK (1) DK3180339T3 (enExample)
EA (1) EA031424B1 (enExample)
ES (1) ES2711763T3 (enExample)
HR (1) HRP20190336T1 (enExample)
HU (1) HUE043915T2 (enExample)
IL (1) IL249844B (enExample)
LT (1) LT3180339T (enExample)
ME (1) ME03303B (enExample)
MX (1) MX2017001835A (enExample)
NZ (1) NZ728073A (enExample)
PE (1) PE20170193A1 (enExample)
PH (1) PH12017500231A1 (enExample)
PL (1) PL3180339T3 (enExample)
PT (1) PT3180339T (enExample)
RS (1) RS58355B1 (enExample)
SG (1) SG11201700999YA (enExample)
SI (1) SI3180339T1 (enExample)
TR (1) TR201902023T4 (enExample)
TW (1) TWI723959B (enExample)
UA (1) UA118887C2 (enExample)
WO (1) WO2016023858A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
EA038950B1 (ru) 2016-05-19 2021-11-12 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производных 6-алкинил-пиридина
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN110475567A (zh) * 2017-03-31 2019-11-19 勃林格殷格翰国际有限公司 抗癌组合疗法
JP2022511437A (ja) 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス.エー. Hiv感染の組み合わせ治療
TW202600150A (zh) 2019-01-25 2026-01-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
AU2020356356A1 (en) 2019-09-25 2022-05-12 Debiopharm International S.A. Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
BR112022023753A2 (pt) 2020-06-03 2022-12-20 Boehringer Ingelheim Int Rhabdovírus recombinante que codifica para uma proteína de fusão fc de domínio extracelular cd80
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234360A1 (en) * 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
AU2006255084A1 (en) 2005-06-08 2006-12-14 Novartis Ag Organic compounds
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0720049A2 (pt) 2006-12-07 2014-01-07 Novartis Ag Derivados de piridina utilizados como inibidores de xiap
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina

Also Published As

Publication number Publication date
CA2956123C (en) 2023-02-14
UA118887C2 (uk) 2019-03-25
US9481673B2 (en) 2016-11-01
KR20170036095A (ko) 2017-03-31
AU2015303308A1 (en) 2017-02-02
BR112017002498A2 (pt) 2017-12-05
SG11201700999YA (en) 2017-03-30
BR112017002498B1 (pt) 2022-10-11
AP2017009718A0 (en) 2017-01-31
PH12017500231A1 (en) 2017-07-03
NZ728073A (en) 2022-10-28
ME03303B (me) 2019-07-20
JP2017524013A (ja) 2017-08-24
CN106573930A (zh) 2017-04-19
US20190358218A1 (en) 2019-11-28
JP6250226B2 (ja) 2017-12-20
CN111440164A (zh) 2020-07-24
US20170020859A1 (en) 2017-01-26
EP3180339B1 (en) 2018-12-05
US20180015082A1 (en) 2018-01-18
RS58355B1 (sr) 2019-03-29
PL3180339T3 (pl) 2019-05-31
SI3180339T1 (sl) 2019-03-29
CA2956123A1 (en) 2016-02-18
TWI723959B (zh) 2021-04-11
AU2015303308B2 (en) 2020-01-30
CL2017000326A1 (es) 2017-10-20
US10413536B2 (en) 2019-09-17
CO2017001226A2 (es) 2017-05-10
PT3180339T (pt) 2019-02-27
DK3180339T3 (en) 2019-03-04
MX2017001835A (es) 2017-04-27
ES2711763T3 (es) 2019-05-07
EP3180339A1 (en) 2017-06-21
US20160039814A1 (en) 2016-02-11
HUE043915T2 (hu) 2019-09-30
IL249844B (en) 2019-03-31
EA201790349A1 (ru) 2017-07-31
IL249844A0 (en) 2017-03-30
US9801871B2 (en) 2017-10-31
PE20170193A1 (es) 2017-03-25
CN106573930B (zh) 2020-03-03
CN111440164B (zh) 2023-02-17
HRP20190336T1 (hr) 2019-05-03
TW201619156A (zh) 2016-06-01
LT3180339T (lt) 2019-02-25
EA031424B1 (ru) 2018-12-28
WO2016023858A1 (en) 2016-02-18
AR101479A1 (es) 2016-12-21
KR102445744B1 (ko) 2022-09-20
CY1121273T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
EP2978757B1 (en) Indolinone analogues as brd4 inhibitors
AU2013225173B2 (en) 6 - alkynyl pyridines as SMAC mimetics
EP3036235B1 (en) New bis-amido pyridines
CA2956123C (en) 6-alkynyl-pyridine derivatives as smac mimetics
EP3036228B1 (en) New 6-alkynyl pyridine compounds
RS56333B1 (sr) Triazolopirazini kao brd4 inhibitori za korišćenje u lečenju karcinoma
HK1232873B (en) 6-alkynyl-pyridine derivatives as smac mimetics
HK1232873A1 (en) 6-alkynyl-pyridine derivatives as smac mimetics